Mankind Pharma Secures 'B' ESG Rating from MSCI

Mankind Pharma has secured a 'B' ESG rating from MSCI ESG Ratings and Research Private Limited in a key milestone that validates the company's journey toward better sustainability and governance standards.

The ESG report, dated November 4, 2025, was done on an unsolicited basis, with MSCI not being solicited by Mankind Pharma, which shows that the process was transparent.

The MSCI ESG rating is a measure of how well companies manage environmental, social, and governance factors compared to sector peers. A 'B' grade positions Mankind Pharma in the moderate category, indicating continuous work on strengthening the ESG framework with scope for further action.

Also Read: New Dynamics of Drug Distribution, Free Medicine Schemes in India

The rating has been disclosed on the website of the company and informed to BSE and NSE vide letter, a step that reiterates the commitment of the company toward open communication with investors and stakeholders.

In the pharmaceutical industry, ESG ratings are increasingly a measure of long-term resilience. This recognition comes to Mankind Pharma for its attention to key areas such as responsible manufacturing, employee well-being, ethical governance, and access to affordable medicines. The rating follows increasing investor interest in the sustainability-driven performance of India's leading pharma players.

While a ‘B’ rating signals progress and not perfection, it provides a starting point for further developments. Mankind Pharma will be expected to strengthen its commitment to environmental management, ethical standards, and social responsibility, all of which can improve its position in the ESG landscape and undergird the wider objective of growing sustainably through responsible value creation.